Nuformix plc (NFX.L) Sortino Ratio: 1.92
NFX.L's Sortino Ratio of 1.92 indicates that for each unit of downside volatility, it generates 1.92 units of excess return. The ratio is calculated using historical daily returns over the past 12 months (as of Apr 2, 2026).
Unlike other measures, Sortino only focuses on downside volatility (losses), making it particularly useful for investors more concerned about protecting against drawdowns than overall price swings.
NFX.L Sortino Ratio Rank
NFX.L ranks above 75.5% of all investments in our database based on Sortino Ratio over the past 12 months, indicating above-average returns relative to downside risk taken. Securities are ranked from 0 (worst) to 100 (best).
What moves the rank
- Strong returns with minimal downside volatility → Higher rank
- Severe or frequent drawdowns → Lower rank
- Upside volatility → No impact (Sortino doesn't penalize upside swings)
What you can do with this information
- Above-average downside protection with room for improvement
- Compare against category peers to gauge relative positioning
- Monitor for movement toward top tier or decline toward median
- Consider pairing with top-tier holdings to improve portfolio risk profile
NFX.L Sortino Ratio Market Positioning
The chart shows NFX.L's Sortino Ratio relative to all stocks on our platform, with color zones indicating percentile rankings. Higher ratios indicate better downside-adjusted returns.
- Red zone (bottom 25%): -0.15 or lower
- Yellow zone (middle 50%): -0.15 to 1.93
- Green zone (top 25%): 1.93 or higher
- Top 1%: 5.66+
- Median: 0.86 — half of all investments score higher
How it compares to other similar stocks
The table compares Nuformix plc's Sortino Ratio with other stocks in the Biotechnology industry across multiple time periods, showing how NFX.L's risk-adjusted performance compares to industry peers.
Data shows 1-, 5-, and 10-year periods, plus each stock's all-time average, as of Apr 2, 2026.
| Symbol | Name | 1Y Sortino Ratio | 5Y Sortino Ratio | 10Y Sortino Ratio | All Time Sortino Ratio |
|---|---|---|---|---|---|
| HEMO.L | Hemogenyx Pharmaceuticals plc | 3.73 | |||
| APTA.L | Aptamer Group plc | 2.68 | |||
| OXB.L | Oxford BioMedica plc | 2.59 | |||
| IMM.L | ImmuPharma plc | 2.36 | |||
| AREC.L | Arecor Therapeutics plc | 2.26 | |||
| AVCT.L | Avacta Group plc | 2.13 | |||
| GENF.L | Genflow Biosciences PLC | 2.12 | |||
| FAB.L | Fusion Antibodies plc | 2.11 | |||
| NFX.L | Nuformix plc | 1.92 | |||
| GNS.L | Genus plc | 1.52 |
Historical Sortino Ratio
The chart shows NFX.L's rolling Sortino ratio over time compared to your chosen benchmark. Rising trends indicate improving returns relative to downside risk, while declining trends may signal deteriorating risk-adjusted performance or increased volatility during market stress. Use multiple timeframes to distinguish short-term fluctuations from long-term patterns.
Identify market cycles by observing when NFX.L consistently outperforms (line above benchmark), underperforms (below benchmark), or aligns with the benchmark.
Loading graphics...
Explore NFX.L risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.